PF-06250112

• UNSPSC Description:

  PF-06250112 is a potent, highly selective, orally bioavailable BTK inhibitor with an IC50 of 0.5 nM, shows inhibitory effect toward BMX nonreceptor tyrosine kinase and TEC with IC50s of 0.9 nM and 1.2 nM, respectively[1].

• Target Antigen:

  Btk

• Type:

  Reference compound

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/pf-06250112.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(N)C1=C(N(N=C1C2=CC=C(C=C2)OC3=CC=C(C=C3F)F)[C@@H]4CN(CCC4)C#N)N

• Molecular Weight:

  438.43

• References & Citations:

  [1]Rankin AL, et al. Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis. J Immunol. 2013 Nov 1;191(9):4540-50.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1609465-89-5